Clinical trial
Insulin Glulisine in Type 2 Diabetes Mellitus
NCT00310297 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00310297 |
|---|---|
| Title | Insulin Glulisine in Type 2 Diabetes Mellitus |
| Official title | A Randomized, Open Label, Two-arm, Cross-over Design Study to Compare the Pharmacodynamics and Pharmacokinetics of Insulin Glulisine and Insulin Lispro in Obese Patients With Type 2 Diabetes. |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Insulin Glulisine |
| Start date | Nov 1, 2004 |
| Primary completion | Dec 1, 2004 |
| First posted | Apr 3, 2006 |
| Last update posted | Jan 11, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: